2025 Q4 -tulosraportti
38 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 | ||
2024 Q4 -tulosraportti 31.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·20.9.2025This information about Aspargo Labs, Inc. (AAGO) provides some indication of the potential valuation of a company developing a sildenafil combination product and using the FDCA Section 505(b)(2) approval pathway – the same regulatory pathway that Dare Bioscience is using. Dare has several other products in its pipeline in addition to the sildenafil product, suggesting that Dare should be valued higher than Aspargo. A potential trigger for Dare could arise when Aspargo's IPO discloses the sale price of its stock. ⸻ From Aspargo's SEC filings: "We are seeking approval from the FDA to market Sildenafil Oral Suspension, packaged in a 30 ml bottle and administered via a mechanical pump and metered dose actuator as a drug/device combination product, with the primary mode of action ("PMOA") attributable to sildenafil, by using the clearance pathway defined in Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act of 1938 (the "FDCA"). Section 505(b)(2) provides an accelerated clearance process for new changes in dosage form, strength, formulation, dosing regimen or route of administration of previously approved products if certain conditions are met.” "This prospectus relates to the registration of the resale of up to 176,986,993 shares." “The sales price of our common stock for such private transactions during the year ended December 31, 2023 and the nine-month period ended September 30, 2024, was $0.87 per share. For more information, see “Sale Price History of our Common Stock”.” ⸻ Dare Bioscience is a more diversified biotechnology company with a broader pipeline of products, including non-hormonal contraceptives, vaginal medications and other innovative treatments. One of its key products is sildenafil vaginal gel, which is being developed for the treatment of female sexual dysfunction (FSD) – an indication for which there are currently many approved drugs. Aspargo Labs, on the other hand, is a more focused company that is currently developing only a sildenafil oral suspension for the treatment of erectile dysfunction (ED). The product is intended to be administered via a mechanical pump as a drug/device combination. Both companies use the same regulatory path through the FDA – 505(b)(2) – making them comparable in development strategy. The difference lies in the breadth of the pipeline and the company’s long-term potential. Assuming Aspargos’ IPO at $0.87 per share and all ~177 million registered shares are sold, this would equate to a market capitalization of approximately $154 million. Given Dare’s broader pipeline and similar regulatory position, Dare’s market capitalization should, by comparison, exceed Aspargos’ – assuming the market values pipelines and development potential proportionately. My opinion and no advice. ⸻ Sources: - [ ] Aspargo SEC Filing https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=18098851&View=html - [ ] IPO Financial Filings – Nasdaq https://www.nasdaq.com/market-activity/ipos/financial-filings?dealId=1111226-112542 - [ ] IPO News – Renaissance Capital https://www.renaissancecapital.com/IPO-Center/News/108622/Erectile-dysfunction-drug-formulation-maker-Aspargo-Labs-files-for-a-direct Websites https://darebioscience.comhttps://aspargolabs.com
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
38 päivää sitten
‧48 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·20.9.2025This information about Aspargo Labs, Inc. (AAGO) provides some indication of the potential valuation of a company developing a sildenafil combination product and using the FDCA Section 505(b)(2) approval pathway – the same regulatory pathway that Dare Bioscience is using. Dare has several other products in its pipeline in addition to the sildenafil product, suggesting that Dare should be valued higher than Aspargo. A potential trigger for Dare could arise when Aspargo's IPO discloses the sale price of its stock. ⸻ From Aspargo's SEC filings: "We are seeking approval from the FDA to market Sildenafil Oral Suspension, packaged in a 30 ml bottle and administered via a mechanical pump and metered dose actuator as a drug/device combination product, with the primary mode of action ("PMOA") attributable to sildenafil, by using the clearance pathway defined in Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act of 1938 (the "FDCA"). Section 505(b)(2) provides an accelerated clearance process for new changes in dosage form, strength, formulation, dosing regimen or route of administration of previously approved products if certain conditions are met.” "This prospectus relates to the registration of the resale of up to 176,986,993 shares." “The sales price of our common stock for such private transactions during the year ended December 31, 2023 and the nine-month period ended September 30, 2024, was $0.87 per share. For more information, see “Sale Price History of our Common Stock”.” ⸻ Dare Bioscience is a more diversified biotechnology company with a broader pipeline of products, including non-hormonal contraceptives, vaginal medications and other innovative treatments. One of its key products is sildenafil vaginal gel, which is being developed for the treatment of female sexual dysfunction (FSD) – an indication for which there are currently many approved drugs. Aspargo Labs, on the other hand, is a more focused company that is currently developing only a sildenafil oral suspension for the treatment of erectile dysfunction (ED). The product is intended to be administered via a mechanical pump as a drug/device combination. Both companies use the same regulatory path through the FDA – 505(b)(2) – making them comparable in development strategy. The difference lies in the breadth of the pipeline and the company’s long-term potential. Assuming Aspargos’ IPO at $0.87 per share and all ~177 million registered shares are sold, this would equate to a market capitalization of approximately $154 million. Given Dare’s broader pipeline and similar regulatory position, Dare’s market capitalization should, by comparison, exceed Aspargos’ – assuming the market values pipelines and development potential proportionately. My opinion and no advice. ⸻ Sources: - [ ] Aspargo SEC Filing https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=18098851&View=html - [ ] IPO Financial Filings – Nasdaq https://www.nasdaq.com/market-activity/ipos/financial-filings?dealId=1111226-112542 - [ ] IPO News – Renaissance Capital https://www.renaissancecapital.com/IPO-Center/News/108622/Erectile-dysfunction-drug-formulation-maker-Aspargo-Labs-files-for-a-direct Websites https://darebioscience.comhttps://aspargolabs.com
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 | ||
2024 Q4 -tulosraportti 31.3.2025 |
2025 Q4 -tulosraportti
38 päivää sitten
‧48 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 | ||
2024 Q4 -tulosraportti 31.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·20.9.2025This information about Aspargo Labs, Inc. (AAGO) provides some indication of the potential valuation of a company developing a sildenafil combination product and using the FDCA Section 505(b)(2) approval pathway – the same regulatory pathway that Dare Bioscience is using. Dare has several other products in its pipeline in addition to the sildenafil product, suggesting that Dare should be valued higher than Aspargo. A potential trigger for Dare could arise when Aspargo's IPO discloses the sale price of its stock. ⸻ From Aspargo's SEC filings: "We are seeking approval from the FDA to market Sildenafil Oral Suspension, packaged in a 30 ml bottle and administered via a mechanical pump and metered dose actuator as a drug/device combination product, with the primary mode of action ("PMOA") attributable to sildenafil, by using the clearance pathway defined in Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act of 1938 (the "FDCA"). Section 505(b)(2) provides an accelerated clearance process for new changes in dosage form, strength, formulation, dosing regimen or route of administration of previously approved products if certain conditions are met.” "This prospectus relates to the registration of the resale of up to 176,986,993 shares." “The sales price of our common stock for such private transactions during the year ended December 31, 2023 and the nine-month period ended September 30, 2024, was $0.87 per share. For more information, see “Sale Price History of our Common Stock”.” ⸻ Dare Bioscience is a more diversified biotechnology company with a broader pipeline of products, including non-hormonal contraceptives, vaginal medications and other innovative treatments. One of its key products is sildenafil vaginal gel, which is being developed for the treatment of female sexual dysfunction (FSD) – an indication for which there are currently many approved drugs. Aspargo Labs, on the other hand, is a more focused company that is currently developing only a sildenafil oral suspension for the treatment of erectile dysfunction (ED). The product is intended to be administered via a mechanical pump as a drug/device combination. Both companies use the same regulatory path through the FDA – 505(b)(2) – making them comparable in development strategy. The difference lies in the breadth of the pipeline and the company’s long-term potential. Assuming Aspargos’ IPO at $0.87 per share and all ~177 million registered shares are sold, this would equate to a market capitalization of approximately $154 million. Given Dare’s broader pipeline and similar regulatory position, Dare’s market capitalization should, by comparison, exceed Aspargos’ – assuming the market values pipelines and development potential proportionately. My opinion and no advice. ⸻ Sources: - [ ] Aspargo SEC Filing https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=18098851&View=html - [ ] IPO Financial Filings – Nasdaq https://www.nasdaq.com/market-activity/ipos/financial-filings?dealId=1111226-112542 - [ ] IPO News – Renaissance Capital https://www.renaissancecapital.com/IPO-Center/News/108622/Erectile-dysfunction-drug-formulation-maker-Aspargo-Labs-files-for-a-direct Websites https://darebioscience.comhttps://aspargolabs.com
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt